Omada Health, Inc. (NASDAQ:OMDA – Get Free Report) CEO Sean Duffy sold 12,942 shares of the stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $24.81, for a total transaction of $321,091.02. Following the sale, the chief executive officer owned 411,861 shares of the company’s stock, valued at approximately $10,218,271.41. This represents a 3.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.
Omada Health Price Performance
Shares of NASDAQ:OMDA opened at $24.01 on Wednesday. Omada Health, Inc. has a 1 year low of $10.28 and a 1 year high of $26.92. The company has a market cap of $1.47 billion, a PE ratio of 480.20 and a beta of 1.73. The stock’s 50-day moving average is $20.61 and its 200 day moving average is $16.32.
Omada Health (NASDAQ:OMDA – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.08 earnings per share for the quarter, topping the consensus estimate of ($0.02) by $0.10. The business had revenue of $87.83 million during the quarter, compared to analysts’ expectations of $80.93 million. Omada Health had a return on equity of 2.67% and a net margin of 1.39%. Analysts expect that Omada Health, Inc. will post -0.01 EPS for the current fiscal year.
Institutional Investors Weigh In On Omada Health
Analysts Set New Price Targets
Several research firms recently weighed in on OMDA. Citigroup reiterated an “outperform” rating on shares of Omada Health in a report on Monday, July 20th. Morgan Stanley restated an “overweight” rating and issued a $30.00 price objective on shares of Omada Health in a report on Monday, June 22nd. BTIG Research lifted their target price on shares of Omada Health from $30.00 to $35.00 and gave the company a “buy” rating in a research note on Monday. Citizens Jmp lifted their target price on shares of Omada Health from $21.00 to $27.00 and gave the company a “market outperform” rating in a research note on Monday, July 20th. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $24.00 price target on shares of Omada Health in a research report on Friday. Eleven equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Omada Health currently has a consensus rating of “Moderate Buy” and a consensus target price of $25.67.
View Our Latest Stock Analysis on OMDA
Omada Health Company Profile
Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.
In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.
Read More
- Five stocks we like better than Omada Health
- Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
- AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be
- NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
- Apple’s Next iPhone Could Test How Much Pricing Power Is Left
Receive News & Ratings for Omada Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omada Health and related companies with MarketBeat.com's FREE daily email newsletter.
